Reimagining Population Health Management
Can Genomics Evolve our Sick Care System into a True Healthcare System
Date: December 15, 2020
Time: 11:30 am – 12:30 pm PST
Imagine if our healthcare system could actually prevent us from becoming patients in the first place.
In today’s healthcare, we use only 10% of the data that predicts health outcomes. Genetic information has the potential to radically improve our predictive power and to help risk-stratify the patients at highest and lowest risk of common chronic diseases such as diabetes, cardiovascular disease, and hypertension.
This webinar will explore how using genetics as a routine part of our healthcare can help us improve population health management—by identifying the highest-risk patients and proactively delivering personalized, preventive interventions to the right patients at the right time.
In this webinar, we’ll cover:
- The channels, tools, and delivery methods that could be used for population health management;
- How genomics can be paid for when applied as a population health management tool in the transition to value-based care; and
- How digital health companies should think about building solutions for population health management.
Meet the Panelists
Lisa Alderson (Moderator)
CEO and Co-Founder of Genome Medical
Lisa Alderson is the CEO and Co-Founder of Genome Medical, Inc., a leading genomics technology and services company that is transforming the delivery of medicine by enabling access to genomic-based medicine for everyday care. Through its nationwide network of genetic specialists and efficient Genome Care DeliveryTM technology platform, Genome Medical provides health expertise throughout the genomics journey.
Prior, Ms. Alderson served as the Chief Commercial Officer and Chief Strategy Officer of Invitae (NYSE: NVTA), a rapidly growing genetic information company. She was also the former CEO and president of CrossLoop Inc., a marketplace for technical services (acquired by Nasdaq: AVG). Prior to that, she was part of the start-up team at Genomic Health Inc. (Nasdaq: GHDX), president of Cinema Circle Inc., (acquired by Nasdaq: GAIA) and the former manager of strategic planning at The Walt Disney Co. Lisa also serves on the board of the Kidney Cancer Association. She has a track record of creating, funding and managing high-growth ventures. Lisa has an MBA with distinction from Harvard Business School and a B.A. from Colorado State University, where she graduated Summa Cum Laude.
Tony Slonim, MD, DrPH, FACHE
President and CEO, Renown Health
Dr. Anthony (Tony) Slonim is the president and CEO of Renown Health, one of the nation’s most innovative and progressive health systems based in Reno, Nevada. Tony leads Renown’s charitable mission of “making a genuine difference in the community’s health and well-being,” based on the principles of caring, integrity, collaboration and excellence.
With a focus on caring for patients, members, and the community, Tony has a personal passion for population health. He caught the industry’s attention by launching the Healthy Nevada Project®, the first community based, population health study combining genetic, environmental, social and clinical data to address individual and community health needs. As of January 2020, nearly 50,000 volunteer participants have enrolled in this program statewide and it has become a model for genetic screening at the population level nationwide. Governor Steve Sisolak recently appointed Dr. Slonim as a Commissioner on the Patient Protection Commission, a statewide Commission responsible for improving the access, affordability and quality of healthcare for all Nevadans.
Recognized nationally as a thought leader, Modern Healthcare has named Tony to its Most Influential Physician Executives and Leaders list. He has been honored on Becker’s Hospital Review’s “Physician Leaders to Know” list since 2014. Tony serves as the inaugural editor-in-chief of the American Association of Physician Leader’s (AAPL) Physician Leadership Journal serving the needs of the 15000 physician leaders who subscribe to this bi-monthly publication.
He just recently completed his term as chair of the AHA’s Systems Council.
Chet Robson DO, MHCDS, FAAFP
Chief Clinical Officer, Walgreens
Dr. Robson provides evidence-based leadership for pharmacy, specialty pharmacy, healthcare services, digital innovation and retail merchandising. Dr. Robson is the Medical Director the Walgreens Pandemic Response. He is leading the development of a healthcare destination that integrates primary care, pharmacy and ancillary services such as labs, and digital resources into the flow of people’s lives. He also leads development of pharmacogenomics and clinical research. By utilizing innovative technology, patient-engaging care delivery models, and evidence-based medicine Dr. Robson clinically advances the Walgreens purpose to champion the health and well-being of every community in America.
Education: Dr. Robson did undergraduate studies at the University of Southern California and Eastern Washington University. He obtained his medical degree from Midwestern University and completed a residency in family medicine at LaGrange Memorial Hospital where he was Chief Resident. Dr. Robson practiced as a family medicine physician and became the Chief Medical Information Officer. He received his MBA in healthcare delivery science from the Tuck School of Business and Geisel School of Medicine at Dartmouth College.
Professor Sir Peter Donnelly, FRS FMedSci
Founder and CEO, Genomics plc
Professor Sir Peter Donnelly FRS, FMedSci, is one of the global leaders and pioneers at the interface of human genetics and medicine. He is a Founder and CEO of Genomics plc and Emeritus Professor at the University of Oxford.
Peter grew up in Brisbane and studied for a doctorate in mathematics at Oxford as a Rhodes Scholar. His subsequent decorated academic career has seen his research interests evolve from mathematics and statistics to human genetics, aiming to further our understanding of human biology for the improvement of medicine and healthcare. Peter played a central role in what has come to be known as the “Genetic Revolution” – the explosion in our knowledge of the genetic basis of human diseases and the increasing use of genome sequencing in clinical medicine. From 2007 to 2017 he was Director of Oxford’s Wellcome Centre for Human Genetics, one of the premier international human genetics research institutes.
In 2014, together with Professor Gil McVean, the then inaugural director of Oxford’s Big Data Institute, Peter founded Genomics plc, with the vision of bringing together the best and brightest scientists to bridge the gap between the breakthrough science and the delivery of healthcare for improved patient outcomes. Genomics plc offers earlier and more accurate understanding about individual risk for all of the common chronic diseases and cancers to doctors and their patients. The company also uses insights from genomic variation to accelerate the discovery and development of new medicines. Peter became Genomics plc’s CEO in 2017.
Peter has received numerous honours in recognition of his work, most recently a Knighthood in the 2019 Queen’s Birthday Honours for services to the understanding of human genetics in disease.
Marcia Guida, MS-CH, MBA, MS-HP,CPC
Senior Director, Value Based Contracting and Medicare Network Operations, Aetna CVS Health
Healthcare executive with over thirty years of health plan and provider/practice management experience in value based programming, health systems administration and health policy. Extensive health plan and provider experience with developing, building and management of provider relationships, provider engagement and payment reform activities in the commercial, Medicare Advantage and Medicaid lines of business. Recognized as leader in development of strategy, implementation and operations of health care reform and value based activity including medical/health home, population health, risk and account-able care models. Extensive experience with development of managed care contracts to support transition to a value based environment.
Past and current experience includes leading strategic initiatives for major health plans in collaboration with external partners, both private (e.g. Engleberg Center for Health Care Reform and the Dartmouth Institute for Health Care Policy and Clinical Practice-Brookings Dartmouth) and public (CMS and CMMI). On the provider side, experience includes development and implementation of a standard ACO Operating Model for the second largest Catholic health system in the US. Industry experience includes serving on or co-leading several health industry committees within AHIP, Brookings ACO Learning Network, NQF, URAC, WEDI, American Journal of Managed Care, ACO and Emerging Healthcare Delivery Coalition. Numerous industry speaking engagements on ACOs, provider/payor relationships, pay for performance, quality metrics, social determinants in a value based model. Testified in front of the Senate Health, Education, Labor and Pension Committee (HELP).